Table 2.
Cumulative Incidence of Death After Relapse/Disease Progression v Death As a First Event in COG ALL Trials
| Death As a First or Subsequent Event | Cumulative Incidence (%) |
P * | |||
|---|---|---|---|---|---|
| 1990-1994 | 1995-1999 | 2000-2005 | Overall | ||
| 5-year | |||||
| Relapse/disease progression or secondary malignancies as first event | 12.83 | 9.03 | 7.22 | 9.82 | < .001 |
| Treatment-related death prior to relapse/disease progression | 2.16 | 1.92 | 1.57 | 1.89 | .0335 |
| Unknown or unrelated | 1.37 | 1.36 | 0.81 | 1.19 | .0013 |
| Overall | 16.35 | 12.31 | 9.60 | 12.90 | < .001 |
| 10-year | |||||
| Relapse/disease progression or secondary malignancies as first event | 15.80 | 12.45 | — | 12.98 | < .001 |
| Treatment-related death prior to relapse/disease progression | 2.17 | 1.95 | — | 1.91 | .3413 |
| Unknown or unrelated | 1.89 | 1.67 | — | 1.61 | .7149 |
| Overall | 19.86 | 16.07 | 16.50 | < .001 | |
Abbreviations: ALL, acute lymphoblastic leukemia; COG, Children's Oncology Group.
*
P values in the 5-year category were computed by comparing the corresponding cumulative incidence curves among all three eras; P values in the 10-year category were for comparison between the first two eras (1990-1994 v 1995-1999).